MARKET

LNSR

LNSR

Lensar Inc
NASDAQ
3.250
+0.070
+2.20%
Closed 16:00 02/08 EST
OPEN
3.275
PREV CLOSE
3.180
HIGH
3.275
LOW
3.160
VOLUME
4.11K
TURNOVER
6.78K
52 WEEK HIGH
8.80
52 WEEK LOW
2.150
MARKET CAP
35.83M
P/E (TTM)
-1.5136
1D
5D
1M
3M
1Y
5Y
LENSAR to Present at Two Upcoming Investor Conferences
ORLANDO, Fla., November 22, 2022--LENSAR, Inc. (NASDAQ: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced Nick Curtis, Chief Execu...
Business Wire · 11/22/2022 13:00
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Benzinga · 11/22/2022 08:49
LENSAR GAAP EPS of -$0.39 beats by $0.23, revenue of $7.75M misses by $0.15M
Seekingalpha · 11/09/2022 13:40
LENSAR Q3 EPS $(0.39) Beats $(0.62) Estimate, Sales $7.75M Miss $7.90M Estimate
Benzinga · 11/09/2022 12:05
LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update
ORLANDO, Fla., November 09, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for th...
Business Wire · 11/09/2022 12:00
-- Earnings Flash (LNSR) LENSAR Posts Q3 Revenue $7.7M, vs. Street Est of $7.9M
-- Earnings Flash (LNSR) LENSAR Posts Q3 Revenue $7.7M, vs. Street Est of $7.9M
MT Newswires · 11/09/2022 07:10
LENSAR Announces Application for Certification of the ALLY™ Adaptive Cataract Treatment System in the EU
ORLANDO, Fla., September 08, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the application for cer...
Business Wire · 09/08/2022 11:00
LENSAR Applies for EU Certification of ALLY Adaptive Cataract Treatment System
LENSAR Applies for EU Certification of ALLY Adaptive Cataract Treatment System
MT Newswires · 09/08/2022 08:41
More
About LNSR
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The Company is also developing an integrated cataract treatment system, ALLY Adaptive Cataract Treatment System (ALLY). The ALLY system is designed to combine its existing femtosecond laser technology and a phacoemulsification system into a single unit that allows surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.

Webull offers kinds of LENSAR Inc stock information, including NASDAQ:LNSR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LNSR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LNSR stock methods without spending real money on the virtual paper trading platform.